

Autism Spectrum Disorder

**A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Balovaptan in Children With Autism Spectrum Disorder**

<b>Trial Status</b> Terminated	<b>Trial Runs In</b> 2 Countries	<b>Trial Identifier</b> NCT04049578 WP40877
-----------------------------------	-------------------------------------	--

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

***Trial Summary:***

This was a Phase Ib, multicenter, open-label study in children 2-4 years old with autism spectrum disorder (ASD) to investigate the pharmacokinetics, safety, and tolerability of an oral dose of balovaptan once a day (QD). The study was to consists of a 6-week treatment period to evaluate the pharmacokinetics of balovaptan in 2 to 4 year old children followed by an optional extension period of 48 weeks.

<b>Hoffmann-La Roche</b> Sponsor	<b>Phase 1</b> Phase
-------------------------------------	-------------------------

**NCT04049578 WP40877**  
Trial Identifiers

***Eligibility Criteria:***

<b>Gender</b> All	<b>Age</b> >=2 Years & <= 4 Years	<b>Healthy Volunteers</b> No
----------------------	--------------------------------------	---------------------------------